ACCENDRA HEALTH INC/VA/
No SEC Form 4 filings for $ACH in the last 30 days.
See all $ACH insider activity →Accendra Health (ACH) reported Q2 2026 revenue of $613.2M, down from $681.9M YoY, and adjusted EBITDA of $60.1M, down from $96.6M. The company revised full-year revenue guidance to $2.45B-$2.55B and adjusted EBITDA to $300M-$320M, citing slower growth and collection rate issues. Total debt decreased by $385M to $1.72B. CEO Edward Pesicka announced his retirement by year-end.
Accendra Health (ACH) reported Q2 2026 net revenue of $613.2 million, down from $681.9 million a year earlier, and adjusted EBITDA of $60.1 million versus $96.6 million. Full-year revenue guidance was revised to $2.45 billion to $2.55 billion and adjusted EBITDA to $300 million to $320 million. Debt fell to $1.72 billion as of June 30, 2026.
Accendra Health (NYSE:ACH) said it will drop an at-the-market equity issuance plan, citing recent market conditions, and said the change will not affect operating results or prior financial guidance. The company expects two non-core asset sales to generate about $45 million in cash and reported no drawings on its $300 million revolver. It plans to name a CEO successor by mid-September 2026.
Over the past 7 days, alphai's AI scored 2 news stories mentioning ACH (ACCENDRA HEALTH INC/VA/). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent ACH coverage spans corporate actions, earnings and financial news.
Guidance downgrade and higher debt may pressure the stock, while debt reduction and cost cuts provide some upside.
The call discloses a guidance reset tied to payor collection headwinds and higher expenses, plus liquidity and debt actions that can shift near-term risk and valuation.
Removing the ATM issuance reduces near-term dilution risk, while the mid-September CEO appointment window concentrates attention on transition execution and liquidity planning.
Leadership transition risk and timeline uncertainty could drive near-term sentiment volatility, but no operational guidance or financial numbers were provided.
The company adopted a shareholder rights plan tied to Section 382 ownership-change thresholds, which can affect takeover dynamics and investor positioning.
alphai scores every news story that mentions ACH with an AI model for sentiment and relevance, and aggregates insider trades from ACCENDRA HEALTH INC/VA/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Accendra Health (ACH) reported Q2 2026 revenue of $613.2M, down from $681.9M YoY, and adjusted EBITDA of $60.1M, down from $96.6M. The company revised full-year revenue guidance to $2.45B-$2.55B and adjusted EBITDA to $300M-$320M, citing slower growth and collection rate issues. Total debt decreased by $385M to $1.72B. CEO Edward Pesicka announced his retirement by year-end.
3 min readAccendra Health (ACH) reported Q2 2026 net revenue of $613.2 million, down from $681.9 million a year earlier, and adjusted EBITDA of $60.1 million versus $96.6 million. Full-year revenue guidance was revised to $2.45 billion to $2.55 billion and adjusted EBITDA to $300 million to $320 million. Debt fell to $1.72 billion as of June 30, 2026.
6 min readAccendra Health (NYSE:ACH) said it will drop an at-the-market equity issuance plan, citing recent market conditions, and said the change will not affect operating results or prior financial guidance. The company expects two non-core asset sales to generate about $45 million in cash and reported no drawings on its $300 million revolver. It plans to name a CEO successor by mid-September 2026.
4 min readAccendra Health (NYSE: ACH) said CEO Edward A. Pesicka plans to retire by end-2026 and step down from the board before year-end. The board has started a successor search and will evaluate candidates to appoint a new president and CEO. The company cited prior transactions and management changes as part of the timing.
3 min readACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 3 tm2622667d3_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 SECTION 382 RIGHTS AGREEMENT Dated as of August 10, 2026 between ACCENDRA HEALTH, INC. and Computershare TRUST COMPANY, N.A. , as Rights Agent TABLE OF CONTENTS Page Section 1. Definitions 1 Section 2. Appointment of Rights A
5 min readAccendra Health (ACH) reported Q2 2026 revenue of $613.2 million, down from $681.9 million a year earlier, with GAAP net loss of $89.1 million ($1.16/share). Non-GAAP adjusted net loss was $14.3 million. Adjusted EBITDA fell to $60.1 million and free cash flow was -$25.1 million. The company guided FY2026 revenue $2.45-$2.55 billion and adjusted EBITDA $300-$320 million, and adopted a tax asset preservation plan.
5 min readACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622667d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Accendra Health Reports Second Quarter 2026 Financial Results Reduced Total Debt By $385 Million In Second Quarter CEO Ed Pesicka Announces Intention To Retire By The End of 2026 RICHMOND, VA – August 10, 2026 – Accendra
6 min readACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000075252 0000075252 2026-08-10 2026-08-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readAccendra Health Inc. (NYSE:ACH) said on June 23 it completed exchange offers for its 4.5% senior notes due 2029 and 6.625% senior notes due 2030. The notes were exchanged for new 9% senior secured first-lien notes due 2032 and 9.75% senior secured second-lien notes due 2033. Accendra expects to issue about $539.25 million first-lien notes and about $698.1 million second-lien notes, while S&P Global Ratings affirmed a 'B' issuer rating and moved outlook to stable.
3 min readACCENDRA HEALTH INC/VA/ (ACH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 d100115dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 AMENDMENT NO. 4 TO CREDIT AGREEMENT AND CONSENT AMENDMENT NO. 4 TO CREDIT AGREEMENT AND CONSENT, dated as of June 15, 2026 (this “ Amendment ”), by and among ACCENDRA HEALTH, INC. (f/k/a OWENS & MINOR, INC.), a Virginia cor
6 min read
